The invention relates to a method of suppressing B1 cell activity in a host (e.g., mammalian, including human) comprising administering to the host an effective amount of IL-12 that significantly suppresses or inhibits B1 cell activity. In addition, the invention relates to a method of treating a B1 cell disorder in a host, comprising administering to the host an effective therapeutic amount of IL-12. The invention further encompasses a method of screening for substances (e.g., proteins, peptides, small molecules) which enhance or suppress the inhibition of B1 cell activity by IL-12. The invention also relates to a substance identified by the methods of screening for a substance which enhances or suppresses IL-12 inhibition of B1 cell activity.
Genetics, Institute; Medical College of Ohio
514/3.8; 514/4.3; 514/7.3; 514/16.6; 514/17.5; 514/17.9; 514/19.6
These materials are free of copyright restrictions and are in the public domain within the United States only. The USPTO reserves the right to assert copyright protection internationally.
The University of Toledo
University of Toledo Libraries
Metzger, Dennis W. and Van, Victor H., "IL-12 inhibition of B1 cell activity" (1997). University of Toledo U.S. Patents. 157.